Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
University of Michigan–Ann Arbor · Dana-Farber Cancer Institute · +8 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
697
total citations
- FWCI
- 47.31
- Percentile
- 100%
- References
- 34
Citations per year
Authors
14Topics & keywords
Topics
Keywords
- Crizotinib
- Medicine
- Anaplastic lymphoma kinase
- Anaplastic large-cell lymphoma
- Internal medicine
- Oncology
- Lymphoma
- Refractory (planetary science)
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.